Linden Thomas Advisory Services LLC Invests $186,000 in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Linden Thomas Advisory Services LLC acquired a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the 4th quarter, Holdings Channel reports. The firm acquired 11,077 shares of the biopharmaceutical company’s stock, valued at approximately $186,000.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Catalyst Pharmaceuticals by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 7,046,487 shares of the biopharmaceutical company’s stock worth $82,373,000 after purchasing an additional 174,739 shares during the last quarter. LSV Asset Management increased its stake in shares of Catalyst Pharmaceuticals by 25.6% during the 3rd quarter. LSV Asset Management now owns 1,240,769 shares of the biopharmaceutical company’s stock worth $14,505,000 after purchasing an additional 253,100 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Catalyst Pharmaceuticals by 6.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 921,327 shares of the biopharmaceutical company’s stock worth $10,770,000 after purchasing an additional 58,018 shares during the last quarter. American Century Companies Inc. increased its stake in shares of Catalyst Pharmaceuticals by 20.6% during the 3rd quarter. American Century Companies Inc. now owns 899,478 shares of the biopharmaceutical company’s stock worth $10,515,000 after purchasing an additional 153,697 shares during the last quarter. Finally, Jupiter Asset Management Ltd. increased its stake in shares of Catalyst Pharmaceuticals by 64.0% during the 3rd quarter. Jupiter Asset Management Ltd. now owns 897,046 shares of the biopharmaceutical company’s stock worth $10,486,000 after purchasing an additional 350,184 shares during the last quarter. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $15.68, for a total transaction of $392,000.00. Following the completion of the sale, the director now owns 348,874 shares of the company’s stock, valued at approximately $5,470,344.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 12.10% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 1.4 %

NASDAQ CPRX opened at $14.89 on Friday. The company has a market capitalization of $1.76 billion, a P/E ratio of 24.41, a P/E/G ratio of 0.81 and a beta of 0.89. Catalyst Pharmaceuticals, Inc. has a 12-month low of $11.09 and a 12-month high of $17.76. The firm has a 50-day moving average price of $15.52 and a two-hundred day moving average price of $14.61.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The firm had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. Equities analysts expect that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current year.

Wall Street Analysts Forecast Growth

CPRX has been the topic of a number of research reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $34.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 22nd. TheStreet upgraded shares of Catalyst Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Tuesday, March 12th. Oppenheimer reiterated an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research note on Wednesday, March 27th. Citigroup initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 14th. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Bank of America initiated coverage on shares of Catalyst Pharmaceuticals in a research note on Thursday, March 7th. They issued a “buy” rating and a $23.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $26.43.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.